An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms VOLFI
- 07 Jun 2017 Biomarkers information updated
- 20 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 20 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.